Gabriele Buda

Prof. Gabriele Buda


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 August 2021 in Medicina
Verified
Journal Article
Open access
PDF file
MGMaria Livia Del Giudice
Maria Livia Del Giudice
Alessandro GozzettiAlessandro Gozzetti
Alessandro Gozzetti
EAElisabetta Antonioli
Elisabetta Antonioli
EOEnrico Orciuolo
Enrico Orciuolo
FGFRANCESCO GHIO
FRANCESCO GHIO
GBGabriele Buda
Gabriele Buda
Background and Objectives: The treatment of Myeloma after the second relapse is still challenging. The aim of the study was to investigate the outcomes of the POM-DEX regimen in real clinical practice. Materials and Methods: We retrospectively and prospectively analyzed 121 patients with MM treated with POM-DEX in three Italian sites in Tuscany. We assessed the efficacy based on IMWG Uniform Response Criteria in 106 patients who had received at least two courses of the POM-DEX regimen. The median time from diagnosis to use of POM-DEX was 65 months. POM-DEX median use was in the fourth-line therapy. 63.6% were exposed to lenalidomide or thalidomide, 40.5% to bortezomib or carfilzomib or ixazomib, 5.8% to mAbs in the immediately preceding line of therapy. Results: ORR was 43.4%. Median PFS and OS were 8.5 and 14 months. Eighty-nine patients received more than two courses: their median PFS and OS were 11 and 16 months. When used as the third line of therapy, median PFS and OS were 9 and 20 months and, when patients received POM-DEX for more than two courses, median PFS and OS were 14.5 and 22.5 months. Conclusions: POM-DEX is effective in RRMM, regardless of the latest exposure to IMiDs, PIs, and mAbs in the previous line of therapy.


27 April 2024
Verified
Conference Paper
Closed access
AAAlberto Aimo
Alberto Aimo
GVGiuseppe Vergaro
Giuseppe Vergaro
VCVincenzo Castiglione
Vincenzo Castiglione
IFIacopo Fabiani
Iacopo Fabiani
Andrea BarisonAndrea Barison
Andrea Barison
MEMichele Emdin
Michele Emdin
Author Listing - Lead/ Submitting Author (we will be communicating with this individual): Name, Institution, City and State where the work was do | POSTER

10 August 2026 in Cancers
Verified
Journal Article
Open access
PDF file
MCMichele Cavo
Michele Cavo
MBMelissa Bersanelli
Melissa Bersanelli
ACAlessandro Corso
Alessandro Corso
CGCarlotta Galeone
Carlotta Galeone
SMSilvia Mangiacavalli
Silvia Mangiacavalli
PMPaolo Mariani
Paolo Mariani
Background/Objectives: The treatment landscape of relapsed/refractory multiple myeloma (RRMM) has significantly evolved with the introduction of novel classes of agents and, more recently, of T-cell-redirecting therapies, including bispecific antibodies (BsAbs). It is essential to enhance and harmonize the therapeutic management of BsAbs within clinical practice. Methods: We performed a modified Delphi expert consensus study on the use of BsAbs targeting the B-Cell Maturation Antigen (BCMA) in patients with triple-class-exposed (TCE) RRMM. The study was conducted in April–November 2025 following established guidelines and best practices for defining consensus. The key phases in the use of anti-BCMA BsAbs were identified and explored. Results: Fifteen Italian hematologists with expertise in the care of TCE RRMM completed two Delphi rounds. Agreement (defined as ≥67% of panelists) was achieved on most of the topics evaluated. In particular, all panelists considered the step-up dosing phase feasible in an outpatient setting, under specific circumstances, and dosing de-escalation in responding patients to reduce the risk of adverse events. For most of them, anti-BCMA BsAb treatment is also feasible in several challenging subgroups, including frail patients (93% agreement) and those with high-risk cytogenetics (93%), extramedullary disease (93%), end-stage renal disease (86%), active plasma cell leukemia (79%), and central nervous system involvement (67%). In addition, agreement (93%) was reached on the possible sequential use of BCMA-targeting therapies, preferentially BsAbs following CAR-T, though a switch in the target antigen should primarily be considered. Conclusions: In this article, we address the main challenges related to the real-world use of anti-BCMA BsAbs in patients with TCE RRMM, offering expert recommendations to complement existing guidelines and support clinical practice.

28 March 2024
Verified
Book Chapter
Closed access
PDF file
GBGabriele Buda
Gabriele Buda
Paolo MorfinoPaolo Morfino
Paolo Morfino
AAAlberto Aimo
Alberto Aimo
AWAshutosh D. Wechalekar
Ashutosh D. Wechalekar

28 April 2024
Verified
Conference Paper
Closed access
GVGiuseppe Vergaro
Giuseppe Vergaro
AAAlberto Aimo
Alberto Aimo
LSLucas Soares
Lucas Soares
AGAssuero Giorgetti
Assuero Giorgetti
DGDario Genovesi
Dario Genovesi
MEMichele Emdin
Michele Emdin
**Author Listing - Lead/ Submitting Author (we will be communicating with this individual): Name, Institution, City and State where the work was | POSTER